The corporate venturing units of three healthcare companies have joined a consortium investing in the $45m series A round of Effector Therapeutics, a US-based biopharmaceutical company named after the eponymous molecule that selectively binds to a protein and regulates its biological activity.
Novartis Venture Funds, GlaxoSmithKline’s SR One and Astellas Venture Management joined with venture capital (VC) firms, including US Venture Partners, Abingworth, Osage University Partners and Mission Bay Capital, in backing Effector.
Effector focuses on developing small molecule drugs to regulate protein synthesis, also known as translation. The funds will support multiple discovery programs and enable acquisition of tumor response data in patients for a lead drug candidate.
Larry Lasky, director at Effector and partner at US Venture Partners, said: “Effector’s is the kind of great science that VCs should be funding to build the pipeline of our next generation of medicines.”
Steve Worland, executive president at Effector, added: “It is particularly rewarding to bring together cutting edge science from the University of California San Francisco with experienced investors willing to fund innovation with sufficient capital to extend product development into the clinic.”

- News & Analysis
- Home
- Global Corporate Venturing
- Global University Venturing
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- Video
- Subscribe
- Newsletters
- Events
Effector Therapeutics starts with $45m
Jun 1, 2013 •
LEADERSHIP SOCIETY
Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.More featured content
UK economic development bank to boost backing for spinout funds The British Business Bank plans to invest in university spinout investment funds outside of the Golden Triangle.UK economic development bank to boost backing for spinout funds
The British Business Bank plans to invest in university spinout investment funds outside of the Golden Triangle.
UK’s University of Liverpool joins Northern Gritstone spinout investor It becomes the fourth academic institution in the north of England to join the university spinout investor.UK’s University of Liverpool joins Northern Gritstone spinout investor
It becomes the fourth academic institution in the north of England to join the university spinout investor.
Cherie van Wensveen joins Australian spinout fund Uniseed Van Wensveen worked in commercialisation at Austrialian government research organisation CSIRO for more more than three years before joining the ventures fund.Cherie van Wensveen joins Australian spinout fund Uniseed
Van Wensveen worked in commercialisation at Austrialian government research organisation CSIRO for more more than three years before joining the ventures fund.
About us
Global University Venturing (GUV) is where tech transfer, academic and investment experts meet to explore the latest ideas and technologies driving innovation forward. We drive the discussions and share best practices that are critical to the success of spinouts, scaleouts and innovation programmes. Our aim is to help improve the processes of bringing innovations from academia to global markets and facilitate their integration into the broader business ecosystem.
Navigation
test regLogin
Not yet subscribed?
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.